Insider accounts spur a reported bidding war for Amylin

Amylin Pharmaceuticals ($AMLN) is involved in intense buyout negotiations with at least a pair of Big Pharma suitors, according to Bloomberg. The business news service once again quotes insiders, this time saying that Sanofi ($SNY) and Merck ($MRK) have each offered $25 a share, or $4 billion, for the diabetes drug company. And Takeda Pharmaceutical Industries and Bristol-Myers Squibb ($BMY), which reportedly got the ball rolling, are preparing new offers as several others ponder getting into the bidding war. Nothing has ever been publicly confirmed about this process. But if nothing else, Bloomberg is spurring a bidding war with its regular stream of insider accounts--which is exactly what Amylin wants. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.